“…The management of levodopa-induced dyskinesia (LID) remains a significant unmet need in the treatment of Parkinson’s disease (PD) ( Huot et al, 2022 ; Bastide et al, 2015 ; Bove and Calabresi, 2022 ; Huot et al, 2013 ). Levodopa, the biosynthetic precursor to dopamine (DA), has been the predominant symptomatic treatment for PD for more than five decades ( Bastide et al, 2015 ; Rascol et al, 2022 ; Tanner et al, 2020 ; Belujon et al, 2010 ). Though the dyskinetic side effects of long-term levodopa use are well-documented, effective therapies for LID remain elusive (for review ( Huot et al, 2022 ; Bastide et al, 2015 )).…”